ProKidney Corp. PROK

Updated: 9 Aug 2026

NASDAQ | Biotech | Biotechnology and cell therapy

No signal published yet

We already track ProKidney and collect the news. No signal is published yet — follow the company free and we will email you when that changes, or run a quick check now.

Follow ProKidney free Follow free

Email when we publish a signal or something material happens · Sunday weekly brief

No card · No time limit on free tier · Upgrade when you need more

Free
No email, no account, no signup.
Exchange
NASDAQ
Type
Biotech
Sector
Biotechnology and cell therapy
We're already tracking ProKidney Corp. — here are the latest events we've registered

Recent News

  • On June 2, 2026, ProKidney announced the appointment of Kenneth Locke as Chief Technical Officer to lead technical operations and supply chain as the company advances rilparencel toward potential commercialization. On May 15, 2026, the company reported its first-quarter 2026 financial results, ending the quarter with $224.9 million in liquid assets to support operations into mid-2027.

What Firelda Watch includes for ProKidney Corp.

Add the company to your watchlist and get all of this automatically.

  • Free: 3 companies on your watchlist
  • Change history and monitoring for every company you follow
  • Sunday weekly brief — a short weekly roundup
  • Watch/Ultra: same-day email when something material happens
Want to see what a finished analysis looks like?
View a sample analysis
This is a real Firelda analysis. Your analysis of ProKidney Corp. will be delivered in the same format.

Want to follow ProKidney Corp.? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.

Follow ProKidney free Follow free

Email when we publish a signal or something material happens · Sunday weekly brief

No card · No time limit on free tier · Upgrade when you need more

ProKidney Corp. PROK
ProKidney — follow and we'll monitor it
Follow ProKidney free Follow free
Firelda provides general information and analysis, not personal investment advice. Content does not consider your financial situation or goals. Investments can rise and fall in value. Always do your own research.